Natco Pharma
Tracked across 4 events · 28 articles · First seen Mar 20, 2025 · Last active Jun 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Natco Pharma is a key player in launching generic semaglutide in India at a significantly lower price, aiming to capture a substantial share of the weight-loss drug market.
Mar 20, 2026 · 8 articles
Business
Impact: Natco Pharma is one of several Indian companies that launched generic versions of semaglutide, increasing competition for Novo Nordisk.
Mar 30, 2026 · 8 articles
Business
Impact: Natco Pharma is one of the Indian generic drugmakers that will likely offer lower-priced versions of semaglutide once the patent expires.
Nov 11, 2025 · 6 articles
Business
Impact: Natco Pharma continues to be an investor in Pee Safe.
Mar 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Natco Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard